The Lead

Biden administration proposes changing how monkeypox vaccine is administered

By: - August 10, 2022 11:12 am
Health workers sit at a table at a pop-up monkeypox vaccination clinic which opened today by the Los Angeles County Department of Public Health at the West Hollywood Library on Aug. 3, 2022, in West Hollywood, California. California Gov. Gavin Newsom declared a state of emergency on Aug. 1 over the monkeypox outbreak which continues to grow globally. (Mario Tama/Getty Images)

WEST HOLLYWOOD, CALIFORNIA – AUGUST 03: Health workers sit at a table at a pop-up monkeypox vaccination clinic which opened today by the Los Angeles County Department of Public Health at the West Hollywood Library on August 3, 2022 in West Hollywood, California. California Governor Gavin Newsom declared a state of emergency on August 1st over the monkeypox outbreak which continues to grow globally. (Photo by Mario Tama/Getty Images)

WASHINGTON — The Biden administration has begun encouraging health care providers to change the way they’re administering vaccines to protect against monkeypox, in an attempt to stretch out doses fivefold.

The latest shift in strategy comes as the administration races to curtail the spread of the virus, which jumped from 778 cases one month ago on July 9 to 9,493 diagnosed as of Tuesday. The upswing in cases has left many local health departments scrambling to keep up with demand for the vaccine.

By administering the Jynneos vaccine just under the skin, or intradermally, instead of below the layers of fat in the arm, or subcutaneously, officials said they expect health care workers will be able to get up to five doses out of every vial, instead of the current one-vial-one-dose approach.

Local health officials, orgs educate communities on Monkeypox emergency | Friday Morning Coffee

Children will still be given the two-dose vaccine subcutaneously.

“As part of the alternative approach under the (Emergency Use Authorization) one-fifth of the current vaccine dose would be administered intradermally, rather than subcutaneously as the vaccine was originally approved,” U.S. Food and Drug Administration Commissioner Robert M. Califf said Tuesday.

A clinical study of the Jynneos vaccine published before its approval in 2019 showed a similar immune response for people given one-fifth of the dose intradermally as to those given the full dose subcutaneously, Califf said.

Those who received the vaccine intradermally did experience some mild side effects, including redness, firmness, itchiness and swelling at the injection site, but those “were all manageable,” Califf said.

If a person got their first vaccine dose subcutaneously, the FDA recommendation is that they get their second dose intradermally, Califf said.

CDC resources

To help health care providers administer the different type of shot, the Centers for Disease Control and Prevention will distribute “educational resources,” including a video, according to Director Rochelle Walensky.

“Some health care providers may not be as familiar with intradermal administration where you deliver the vaccine into the layer of skin just underneath the top layer compared to the more traditional subcutaneous administration which goes into the fat layer underneath the skin,” she said.

To aid in vaccine distribution and free up resources to address the ever-increasing case count, U.S. Health and Human Services Secretary Xavier Becerra declared monkeypox a public health emergency last week.

The United States so far has distributed more than 670,000 vials of vaccine with 441,000 more vials ready to be distributed under the new recommendation where each vial could be used for five doses.

Federal officials declare a public health emergency for monkeypox

Some public health departments, including Washington, D.C., and New York City, have begun offering a one-dose regime, instead of the two doses in order to try to get some level of protection to more people.

Peter Marks, director of the Center for Biologics Evaluation and Research at the FDA, said the new dosing regimen for Jynneos should help ensure people can get both doses.

“We feel pretty strongly that the two doses are necessary, in part, because we simply don’t have any evidence out six, eight, three months later, after a single dose, to know that people will be adequately protected,” Marks said.

“And we don’t want to give people a false sense of security if they resume activities that they had put a pause on because they erroneously think that they’re protected.”

Our stories may be republished online or in print under Creative Commons license CC BY-NC-ND 4.0. We ask that you edit only for style or to shorten, provide proper attribution and link to our web site. Please see our republishing guidelines for use of photos and graphics.

Jennifer Shutt
Jennifer Shutt

Jennifer covers the nation’s capital as a senior reporter for States Newsroom. Her coverage areas include congressional policy, politics and legal challenges with a focus on health care, unemployment, housing and aid to families.